Plus, the addition of ATO to APL treatment regimens was not associated with significant improvements in coagulopathy-associated markers such as platelet count, PT, fibrinogen levels, and/or D-dimer levels [116]. The gene discussed is F2; the disease is acute promyelocytic leukemia.